RAD50 targeting impairs DNA damage response and sensitizes human breast cancer cells to cisplatin therapy

Cancer Biology and Therapy

Volumn 15, Issue 6, 2014, Pages 777-788

  Flores Pérez, Ali ^a   Rafaelli, Lourdes E ^a   Ramírez Torres, Nayeli ^a   Aréchaga Ocampo, Elena ^b   Frías, Sara ^a   Sánchez, Silvia ^a   Marchat, Laurence A ^c   Hidalgo Miranda, Alfredo ^d   Quintanar Jurado, Valeria ^d   Rodríguez Cuevas, Sergio ^e   Bautista Piña, Verónica ^e   Carlos Reyes, Ángeles ^f   López Camarillo, César ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^d INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

^e Institute of Breast Diseases FUCAM   (Mexico)

^f INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Breast cancer; Chemosensitization; Chromosomal aberrations; Cisplatin; DNA damage; Doxorubicin; Histone H2AX; Paclitaxel; RAD50 targeting

Indexed keywords

CISPLATIN; DOXORUBICIN; HISTONE H2AX; PACLITAXEL; RAD50 PROTEIN; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; H2AFX PROTEIN, HUMAN; HISTONE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; RAD50 PROTEIN, HUMAN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CELL COUNT; CELL DEATH; CELL VIABILITY; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG POTENTIATION; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METAPHASE; MONOTHERAPY; PROTEIN EXPRESSION; RNA INTERFERENCE; TISSUE MICROARRAY; BREAST TUMOR; ENZYMOLOGY; FEMALE; GENE SILENCING; GENETICS; MCF 7 CELL LINE; METABOLISM; PAGET NIPPLE DISEASE; PROTEIN PROCESSING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CISPLATIN; DNA DAMAGE; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HISTONES; HUMANS; MCF-7 CELLS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS;

EID: 84901719361     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.28551     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300; PMID:20610543; http://dx.doi.org/10.3322/caac.20073
2. Colozza M, Gori S, Mosconi AM, Belsanti V, Basurto C, Rossetti R, Di Costanzo F, Buzzi F, Bacchi M, Davis S, et al. Chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in patients with metastatic breast cancer. Am J Clin Oncol 1989; 12:137-41; PMID:2705403; http://dx.doi.org/10. 1097/00000421-198904000-00010
3. Lin C, Chen DR, Chang KJ, Chang TW, Wang HC. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancers. Cancer Chemother Pharmacol 2012; 69:1363-8; PMID:22349922; http://dx.doi.org/10.1007/s00280-012-1841-y
4. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep 2003; 10:1663-82; PMID:14534679
5. Chválová K, Brabec V, Kaspárková J. Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin. Nucleic Acids Res 2007; 35:1812-21; PMID:17329374; http://dx.doi.org/10.1093/nar/gkm032
6. Lønning PE. Molecular basis for therapy resistance. Mol Oncol 2010; 4:284-300; PMID:20466604; http://dx.doi.org/10.1016/j.molonc.2010.04.005
7. Mocellin S. Editorial: cancer chemoresistance and DNA repair. Curr Med Chem 2012; 19:3857; PMID:22788737; http://dx.doi.org/10.2174/092986712802002545
8. Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434:864-70; PMID:15829956; http://dx.doi.org/10.1038/nature03482
9. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr., Kastrinakis NG, Levy B, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907-13; PMID:15829965; http://dx.doi.org/10.1038/ nature03485
10. Bartek J, Lukas J, Bartkova J. DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'. Cell Cycle 2007; 6:2344-7; PMID:17700066; http://dx.doi.org/10.4161/cc.6.19.4754
11. Li SX, Sjolund A, Harris L, Sweasy JB. DNA repair and personalized breast cancer therapy. Environ Mol Mutagen 2010; 51:897-908; PMID:20872853; http://dx.doi.org/10.1002/em.20606
12. Quiros S, Roos WP, Kaina B. Rad51 and BRCA2 - New molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS One 2011; 6:e27183; PMID:22073281; http://dx.doi.org/10.1371/journal.pone.0027183
13. Yadav A, Kumar B, Teknos TN, Kumar P. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther 2011; 10:1241-51; PMID:21551262; http://dx.doi.org/10.1158/1535-7163.MCT-11-0004
14. Chernikova SB, Game JC, Brown JM. Inhibiting homologous recombination for cancer therapy. Cancer Biol Ther 2012; 13:61-8; PMID:22336907; http://dx.doi.org/10.4161/cbt.13.2.18872
15. Fleck O, Nielsen O. DNA repair. J Cell Sci 2004; 117:515-7; PMID:14730007; http://dx.doi.org/10.1242/jcs.00952
16. Xie A, Kwok A, Scully R. Role of mammalian Mre11 in classical and alternative nonhomologous end joining. Nat Struct Mol Biol 2009; 16:814-8; PMID:19633669; http://dx.doi.org/10.1038/nsmb.1640
17. Lamarche BJ, Orazio NI, Weitzman MD. The MRN complex in double-strand break repair and telomere maintenance. FEBS Lett 2010; 584:3682-95; PMID:20655309; http://dx.doi.org/10.1016/j.febslet.2010.07.029
18. Heikkinen K, Rapakko K, Karppinen SM, Erkko H, Knuutila S, Lundán T, Mannermaa A, Børresen-Dale AL, Borg A, Barkardottir RB, et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 2006; 27:1593-9; PMID:16474176; http://dx.doi.org/ 10.1093/carcin/bgi360
19. Hsu HM, Wang HC, Chen ST, Hsu GC, Shen CY, Yu JC. Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex. Cancer Epidemiol Biomarkers Prev 2007; 16:2024-32; PMID:17932350; http://dx.doi.org/10.1158/1055-9965.EPI-07-0116
20. Heikkinen K, Karppinen SM, Soini Y, Mäkinen M, Winqvist R. Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. J Med Genet 2003; 40:e131; PMID:14684699; http://dx.doi.org/10.1136/jmg.40.12.e131
21. Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T, Mistrik M, Aittomäki K, Blomqvist C, Heikkilä P, et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol 2008; 2:296-316; PMID:19383352; http://dx.doi.org/10.1016/j.molonc.2008.09.007
22. Angèle S, Treilleux I, Brémond A, Tanière P, Hall J. Altered expression of DNA double-strand break detection and repair proteins in breast carcinomas. Histopathology 2003; 43:347-53; PMID:14511253; http://dx.doi.org/10.1046/j.1365-2559.2003.01713.x
23. Söderlund K, Stål O, Skoog L, Rutqvist LE, Nordenskjöld B, Askmalm MS. Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer. Int J Radiat Oncol Biol Phys 2007; 68:50-8; PMID:17337132; http://dx.doi.org/10.1016/j.ijrobp.2006.12.005
24. Figures MR, Wobb J, Araki K, Liu T, Xu L, Zhu H, O'Malley BW Jr., Li D. Head and neck squamous cell carcinoma targeted chemosensitization. Otolaryngol Head Neck Surg 2009; 141:177-83; PMID:19643248; http://dx.doi.org/10.1016/j. otohns.2009.04.024
25. Abuzeid WM, Jiang X, Shi G, Wang H, Paulson D, Araki K, Jungreis D, Carney J, O'Malley BW Jr., Li D. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J Clin Invest 2009; 119:1974-85; PMID:19487811; http://dx.doi.org/10.1172/JCI33816
26. nd, Duba D, Zhan Q, Kohn KW, Fornace AJ Jr., O'Connor PM. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995; 55:1649-54; PMID:7712469
27. Zhong H, Bryson A, Eckersdorff M, Ferguson DO. Rad50 depletion impacts upon ATR-dependent DNA damage responses. Hum Mol Genet 2005; 14:2685-93; PMID:16087684; http://dx.doi.org/10.1093/hmg/ddi302
28. Zhong ZH, Jiang WQ, Cesare AJ, Neumann AA, Wadhwa R, Reddel RR. Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres. J Biol Chem 2007; 282:29314-22; PMID:17693401; http://dx.doi.org/10.1074/jbc.M701413200
29. Icli F, Akbulut H, Uner A, Yalcin B, Baltali E, Altinbas M, Coşkun S, Komurcu S, Erkisi M, Demirkazik A, et al.; Oncology Group. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. Br J Cancer 2005; 92:639-44; PMID:15726120; http://dx.doi.org/10.1038/sj.bjc.6602388
30. Lopez-Camarillo C, Marchat LA, Rodriguez-Cuevas S, Arechaga-Ocampo E, Perez-Plasencia C, Castañeda-Ortiz EJ, Fonseca MA. DNA repair as a novel therapeutic target in breast cancer. In DNA Repair: New Research. Edited by Nova Science Publishers, Inc. New York, 2011.
31. Williams GJ, Lees-Miller SP, Tainer JA. Mre11-Rad50-Nbs1 conformations and the control of sensing, signaling, and effector responses at DNA double-strand breaks. DNA Repair (Amst) 2010; 9:1299-306; PMID:21035407; http://dx.doi.org/10.1016/j.dnarep.2010.10.001
32. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, Pommier Y. GammaH2AX and cancer. Nat Rev Cancer 2008; 8:957-67; PMID:19005492; http://dx.doi.org/10.1038/nrc2523
33. Fonseca-Sánchez MA, Rodríguez Cuevas S, Mendoza-Hernández G, Bautista-Piña V, Arechaga Ocampo E, Hidalgo Miranda A, Quintanar Jurado V, Marchat LA, Alvarez-Sánchez E, Pérez Plasencia C, et al. Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade. Int J Oncol 2012; 41:670-80; PMID:22614840